Back to Search

Orforglipron for Overweight with Obesity Risks

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Recruiting Phase 3 Interventional Study
Overweight Prediabetic State Prehypertension Obesity, Abdominal
More trials: Hypertension clinical trials· Hypertension trials in Alabama
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
2,001 (estimated)
Sponsor
Eli Lilly and Company · Industry
Who this trial is looking for

This trial is looking for people who are overweight and at risk of developing obesity-related health issues. Participants will take orforglipron and will be monitored to see if it helps reduce these risks.

Are You a Good Fit for This Trial?
Rules you out Type 1 diabetesType 2 diabetesHypertensionDyslipidemia

You may be able to join if

  • I have a waist-to-height ratio of 0.5 or higher.
  • I have at least one obesity-related health issue, like prediabetes.
  • I have tried to lose weight before but was unsuccessful.
  • I have a BMI between 25 and 29.9.

You may not be able to join if

  • I have type 1 or type 2 diabetes.
  • I have not had a stable weight in the last 90 days.
  • I have been diagnosed with obesity or have a BMI of 30 or higher.
  • I have taken weight loss medications in the last 180 days.
  • I have had or plan to have surgery for obesity.
  • I have hypertension or a history of it.
  • I have dyslipidemia or a history of it.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Have an increased waist-to-height ratio of ≥0.5 * Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia) * Have at least one unsuccessful attempt to reduce body weight based on diet and exercise * Have a BMI greater than or equal to …
Contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

317-615-4559

LillyTrials@Lilly.com

CONTACT

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

CONTACT

NCT ID: NCT07794579 Source: ClinicalTrials.gov